clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2023-101-4-5-188-193clinmed-536Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПатофизиологическая роль дисбиоза кишечника при сахарном диабете 2-го типа и антидиабетический потенциал пробиотиков, пребиотиков и трансплантации фекальной микробиотыThe pathophysiological role of intestinal dysbiosis in type 2 diabetes mellitus and the anti-diabetic potential of probiotics, prebiotics and fecal microbiota transplantationhttps://orcid.org/0000-0003-4973-039XАйтбаевК. А.AitbaevK. A.

Айтбаев Кубаныч Авенович  — д-р мед. наук, профессор, руководитель лаборатории патологической физиологии, член правления Общества специалистов по хронической болезни почек Кыргызстана

720040, Бишкек

Aitbaev Kubanych A.

720040, Bishkek

https://orcid.org/0000-0001-8513-9279МуркамиловИ. Т.MurkamilovI. T.

Муркамилов Илхом Торобекович — д-р мед. наук, доцент кафедры факультетской терапии; старший преподаватель, нефролог; председатель правления Общества специалистов по хронической болезни почек Кыргызстана

720020, Бишкек

720000, Бишкек

Murkamilov Ilkhom T.

720020, Bishkek

720000, Bishkek

murkamilov.i@mail.ruhttps://orcid.org/0000-0002-7653-0433МуркамиловаЖ. А.MurkamilovaZh. A.

Муркамилова Жамила Абдилалимовна — заочный аспирант кафедры терапии № 2 медицинского факультета

720000, Бишкек

Murkamilova Zhamila A.

720000, Bishkek

https://orcid.org/0000-0002-2682-4417ФоминВ. В.FominV. V.

Фомин Виктор Викторович — д-р мед. наук, профессор, член-корр. РАН, зав. кафедрой факультетской терапии №1 Института клинической медицины им. Н.В. Склифосовского, проректор по инновационной и клинической деятельности

119991, Москва

Fomin Viktor V.

119991, Moscow

https://orcid.org/0000-0003-3007-8127КудайбергеноваИ. О.KudaibergenovaI. O.

Кудайбергенова Индира Орозобаевна (Kudaibergenova Indira O.) — д-р мед. наук, профессор, ректор

720020, Бишкек

Kudaibergenova Indira O.

720020, Bishkek

ЮсуповаТ. Ф.YusupovaT. F.

Юсупова Турсуной Фуркатовна — студентка 5-го курса медицинского факультета

723500, Ош

Yusupova Tursunoy F.

723500, Osh

ЮсуповФ. А.YusupovF. A.

Юсупов Фуркат Абдулахатович — д-р мед. наук, профессор, зав. кафедрой неврологии, нейрохирургии и психиатрии медицинского факультета; член правления Общества специалистов по хронической болезни почек Кыргызстана, главный невролог Южного региона Кыргызстана

723500, Ош

Yusupov Furkat A.

723500, Osh

Научно-исследовательский институт молекулярной биологии и медициныКыргызстанScientifi c and Research Institute of Molecular Biology and MedicineKyrgyzstanКыргызская государственная медицинская академия имени И.К. Ахунбаева; ГОУ ВПО «Кыргызско-Российский славянский университет имени первого президента Российской Федерации Б.Н. Ельцина»КыргызстанKyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz-Russian Slavic University named after the First President of Russian Federation B.N. YeltsinKyrgyzstanГОУ ВПО «Кыргызско-Российский славянский университет имени первого президента Российской Федерации Б.Н. Ельцина»КыргызстанKyrgyz-Russian Slavic University named after the First President of Russian Federation B.N. YeltsinKyrgyzstanФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian FederationКыргызская государственная медицинская академия имени И.К. АхунбаеваКыргызстанKyrgyz State Medical Academy named after I.K. AkhunbaevKyrgyzstanОшский государственный университетКыргызстанOsh State UniversityKyrgyzstan2023310520231014-5188193Copyright © Айтбаев К.А., Муркамилов И.Т., Муркамилова Ж.А., Фомин В.В., Кудайбергенова И.О., Юсупова Т.Ф., Юсупов Ф.А., 20232023Айтбаев К.А., Муркамилов И.Т., Муркамилова Ж.А., Фомин В.В., Кудайбергенова И.О., Юсупова Т.Ф., Юсупов Ф.А.Aitbaev K.A., Murkamilov I.T., Murkamilova Z.A., Fomin V.V., Kudaibergenova I.O., Yusupova T.F., Yusupov F.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/536

Сахарный диабет (СД) 2-го типа— мультифакториальное заболевание, в развитии которого ожирение играет ключевую роль. Полагают, что глобальный рост распространенности СД 2-го типа и ожирения, принявший в последнее время характер эпидемии, обусловлен урбанизацией, снижением физической активности и повышением доступности калорийной пищи. Недавно в патофизиологии СД 2-го типа обнаружен еще один «игрок» — кишечная микробиота (КМ). Многочисленными исследованиями показана связь КМ и СД 2-го типа. В обзоре рассматриваются механизмы, посредством которого КМ способствует развитию этого заболевания. Приведены результаты экспериментальных и клинических исследований по изучению эффективности использования пробиотиков, пребиотиков и трансплантации фекальной микробиоты в качества средства профилактики и терапии СД 2-го типа.

Type 2 diabetes mellitus (DM2) is a multifactorial disease, and obesity plays the key role in the development thereof. It is believed that the global rise in vast proliferation of DM2 and obesity, recently viewed as an epidemic, is caused by urbanization, reduced physical activity and widely available high-calorie food. Recently, another “player” in the pathophysiology of type 2 diabetes mellitus has been discovered — the intestinal microbiota (IM). Numerous studies have shown the connection between the development of type 2 diabetes mellitus and IM. The review discusses the mechanisms, through which IM contributes to the development of DM2. The results of experimental and clinical studies on the eff ectiveness of the use of probiotics, prebiotics and fecal microbiota transplantation as a method of prevention and treatment of type 2 diabetes mellitus are given.

сахарный диабетинсулиновая резистентностьсубклиническое воспалениекишечная микробиотадисбиоз кишечникапробиотикипребиотикитрансплантация фекальной микробиотыdiabetes mellitusinsulin resistancesubclinical infl ammationintestinal microbiotaintestinal dysbiosisprobioticsprebioticsfecal microbiota transplantationReferencesDanaei G., Finucane M.M., Lu Y. et al. Global burden of metabolic risk factors of chronic diseases collaborating group (blood glucose). National, regional, and global trends in fasting plasma glu cose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 coun tryyears and 2·7 million participants. Lancet. 2011;378: 31–40.Danaei G., Finucane M.M., Lu Y. et al. Global burden of metabolic risk factors of chronic diseases collaborating group (blood glucose). National, regional, and global trends in fasting plasma glu cose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 coun tryyears and 2·7 million participants. Lancet. 2011;378: 31–40.Демидова Т.Ю., Лобанова К.Г., Короткова Т.Н., Харчилава Л.Д. Абнормальная кишечная микробиота и нарушение инкретинового эффекта как причины развития сахарного диабета 2-го типа. Медицинский вестник Юга России. 2022;13(1):24–42. DOI: 10.21886/2219-8075-2022-13-1-24-42Demidova T.Y., Lobanova K.G., Korotkova T.N., Kharchilava L.D. Abnormal gut microbiota and impaired incretin eff ect as a cause of type 2 diabetes mellitus. Medical Herald of the South of Russia. 2022;13(1):24–42. (In Russian)]. DOI: 10.21886/2219-8075-2022-13-1-24-42Демидова Т.Ю., Короткова Т.Н., Кочина А.С. Пищевые волокна как элемент терапии пациентов с сахарным диабетом 2-го типа и сердечно-сосудистыми заболеваниями: простое решение сложной проблемы. Медицинский совет. 2022;16(10):104–109. DOI: 10.21518/2079-701X-2022-16-10-104-109Demidova T.Yu., Korotkova T.N., Kochina A.S. Dietary fi ber is a reliable and apparent element of treatment for patients with type 2 diabetes mellitus and cardiovascular diseases: an easy solution to a complicated problem. Meditsinskiy Sovet. 2022;16(10):104–109. (In Russian)]. DOI: 10.21518/2079-701X-2022-16-10-104-109Cani P.D., Bibiloni R., Knauf C. et al. Changes in gut microbiota control metabolic endotoxemia-induced infl ammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470– 1481.Cani P.D., Bibiloni R., Knauf C. et al. Changes in gut microbiota control metabolic endotoxemia-induced infl ammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470– 1481.Erridge C., Attina T., Spickett C.M. et al. A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial infl ammation. Am. J. Clin. Nutr. 2007;86:1286–1292.Erridge C., Attina T., Spickett C.M. et al. A high-fat meal induces lowgrade endotoxemia: evidence of a novel mechanism of postprandial infl ammation. Am. J. Clin. Nutr. 2007;86:1286–1292.Nolan J.P., Hare D.K., McDevitt J.J. et al. In vitro studies of intestinal endotoxin absorption. I. Kinetics of absorption in the isolated everted gut sac. Gastroenterology. 1977;72:434–439.Nolan J.P., Hare D.K., McDevitt J.J. et al. In vitro studies of intestinal endotoxin absorption. I. Kinetics of absorption in the isolated everted gut sac. Gastroenterology. 1977;72:434–439.Neal M.D., Leaphart C., Levy R. et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J. Immunol. 2006;176: 3070–3079.Neal M.D., Leaphart C., Levy R. et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J. Immunol. 2006;176: 3070–3079.Creely S.J., McTernan P.G., Kusminski C.M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007;292(3):E740–E747.Creely S.J., McTernan P.G., Kusminski C.M. et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 2007;292(3):E740–E747.Hornef M.W., Frisan T., Vanderwalle A. et al. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J. Exp. Med. 2002;195:559–570.Hornef M.W., Frisan T., Vanderwalle A. et al. Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J. Exp. Med. 2002;195:559–570.Ghoshal S., Witta J., Zhong J. et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J. Lipid Res. 2009;50:90–97.Ghoshal S., Witta J., Zhong J. et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J. Lipid Res. 2009;50:90–97.Cani P.D., Bibiloni R., Knauf C. et al. Changes in gut microbiota control metabolic endotoxemia-induced infl ammation in high-fat dietinduced obesity and diabetes in mice. Diabetes. 2008;57:1470–1481.Cani P.D., Bibiloni R., Knauf C. et al. Changes in gut microbiota control metabolic endotoxemia-induced infl ammation in high-fat dietinduced obesity and diabetes in mice. Diabetes. 2008;57:1470–1481.Medzhitov R. Origin and physiological roles of infl ammation. Nature. 2008;454:428–435.Medzhitov R. Origin and physiological roles of infl ammation. Nature. 2008;454:428–435.Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001;1:135–145.Medzhitov R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 2001;1:135–145.Suganami T., Tanimoto-Koyama K., Nishida J. et al. Role of the Tolllike receptor 4/NF-kappaB pathway in saturated fatty acid-induced infl ammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 2007;27:84–91.Suganami T., Tanimoto-Koyama K., Nishida J. et al. Role of the Tolllike receptor 4/NF-kappaB pathway in saturated fatty acid-induced infl ammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 2007;27:84–91.Stamler J.S., Toone E.J., Lipton S.A. et al. (S)NO signals: translocation, regulation, and a consensus motif. Neuron. 1997;18:691–696.Stamler J.S., Toone E.J., Lipton S.A. et al. (S)NO signals: translocation, regulation, and a consensus motif. Neuron. 1997;18:691–696.Беспалова И.Д., Калюжин В.В., Мурашев Б.Ю. и др. Субпопуляционный состав и прооксидантная активность клеток висцеральной жировой ткани пациенток с метаболическим синдромом. Сибирский журнал клинической и экспериментальной медицины. 2022;37(3):114–120. DOI: 10.29001/2073-8552-2022-37-3-114-120Bespalova I.D., Kalyuzhin V.V., Murashev B.Yu. et al. Subpopulation composition and prooxidant activity of visceral adipose tissue cells in patients with metabolic syndrome. The Siberian Journal of Clinical and Experimental Medicine. 2022;37(3):114–120. (In Russian)]. DOI: 10.29001/2073-8552-2022-37-3-114-120WHO — World Health Organization: evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Joint WHO/FAO Expert Consultation on Geneva. Cordoba, Argentina: WHO: 2001.WHO — World Health Organization: evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Joint WHO/FAO Expert Consultation on Geneva. Cordoba, Argentina: WHO: 2001.Gill H., Prasad J. Probiotics, immunomodulation, and health benefi ts. Adv. Exp. Med. Bio. 2008;606:423–454.Gill H., Prasad J. Probiotics, immunomodulation, and health benefi ts. Adv. Exp. Med. Bio. 2008;606:423–454.Prasad J., Gill H.S., Smart J.B. et al. Selection and characterization of Lactobacillus and Bifi dobacterium strains for use as probiotics. Int. Dairy J. 1998; 8:993–1002.Prasad J., Gill H.S., Smart J.B. et al. Selection and characterization of Lactobacillus and Bifi dobacterium strains for use as probiotics. Int. Dairy J. 1998; 8:993–1002.Hummel S., Veltman K., Cichon C. et al. Diff erential Targeting of the E-Cadherin/β-Catenin Complex by Gram-Positive Probiotic Lactobacilli Improves Epithelial Barrier Function. Appl. Environ. Microbiol. 2012;78:1140–1147.Hummel S., Veltman K., Cichon C. et al. Diff erential Targeting of the E-Cadherin/β-Catenin Complex by Gram-Positive Probiotic Lactobacilli Improves Epithelial Barrier Function. Appl. Environ. Microbiol. 2012;78:1140–1147.Jabri B., Ebert E. Human CD8+ intraepithelial lymphosytes: a unique model to study the regulation of eff ector cytotoxic T lymphosytes in tissue. Immunol. Rev. 2007;215:202–214.Jabri B., Ebert E. Human CD8+ intraepithelial lymphosytes: a unique model to study the regulation of eff ector cytotoxic T lymphosytes in tissue. Immunol. Rev. 2007;215:202–214.Yadav H., Jain S., Sinha P.R. Antidiabetic eff ect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23:62–68.Yadav H., Jain S., Sinha P.R. Antidiabetic eff ect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition. 2007;23:62–68.Yadav H., Jain S., Sinha P.R. The eff ect of probiotic Dahi Containing Lactobacillus acidophilus and Lactobacillus casei on Gastropathic Consequences in Diabetic Rats. J. Med. Food. 2008;11:62–68.Yadav H., Jain S., Sinha P.R. The eff ect of probiotic Dahi Containing Lactobacillus acidophilus and Lactobacillus casei on Gastropathic Consequences in Diabetic Rats. J. Med. Food. 2008;11:62–68.Amar J., Chabo C., Waget A. et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 2001;3:559–572.Amar J., Chabo C., Waget A. et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol. Med. 2001;3:559–572.Lee S.K., Yang K.M., Cheon J.H. et al. Anti-infl ammatory mechanism of Lactobacillus rhamnosus GG in lipopolysaccharide-stimulated HT-29 cell. Korean J. Gastroenterol. 2012;60:86–93.Lee S.K., Yang K.M., Cheon J.H. et al. Anti-infl ammatory mechanism of Lactobacillus rhamnosus GG in lipopolysaccharide-stimulated HT-29 cell. Korean J. Gastroenterol. 2012;60:86–93.Moroti C., Souza Magri L.F., Costa M.R. et al. Eff ect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11:29.Moroti C., Souza Magri L.F., Costa M.R. et al. Eff ect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012;11:29.Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A. et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–543.Ejtahed H.S., Mohtadi-Nia J., Homayouni-Rad A. et al. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–543.Andreasen A.S., Larsen N., Pedersen-Skovsgaard T. et al. Eff ects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic infl ammatory response inhuman subjects. Br. J. Nutr. 2010;2010:1831–1838.Andreasen A.S., Larsen N., Pedersen-Skovsgaard T. et al. Eff ects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic infl ammatory response inhuman subjects. Br. J. Nutr. 2010;2010:1831–1838.Luoto R., Laitinen K., Nermes M. et al. Impact of maternal probiotic-supplemented dietary counseling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br. J. Nutr. 2010;103:1792–1799.Luoto R., Laitinen K., Nermes M. et al. Impact of maternal probiotic-supplemented dietary counseling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br. J. Nutr. 2010;103:1792–1799.Latinen K., Poussa T., Isolauri E. Probiotics and dietary counseling contribute to glucose regulation during and after pregnancy: a randomized controlled trial. Br. J. Nutr. 2009;101:1679–1687.Latinen K., Poussa T., Isolauri E. Probiotics and dietary counseling contribute to glucose regulation during and after pregnancy: a randomized controlled trial. Br. J. Nutr. 2009;101:1679–1687.Silk D.B., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: the eff ects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009;29:508–518.Silk D.B., Davis A., Vulevic J., Tzortzis G., Gibson G.R. Clinical trial: the eff ects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 2009;29:508–518.Cani P.D., Knauf C., Iglesias M.A. et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagonlike peptide 1 receptor. Diabetes. 2006;55:1484– 1490.Cani P.D., Knauf C., Iglesias M.A. et al. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagonlike peptide 1 receptor. Diabetes. 2006;55:1484– 1490.Bonsu N.K., Johnson C.S., McLeod K.M. Can dietary fructans lower serum glucose? J. Diabetes. 2011;3:58–66.Bonsu N.K., Johnson C.S., McLeod K.M. Can dietary fructans lower serum glucose? J. Diabetes. 2011;3:58–66.Cani P.D., Lecourt E., Dewulf E.M. et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am. J. Clin. Nutr. 2009;90:1236–1243.Cani P.D., Lecourt E., Dewulf E.M. et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am. J. Clin. Nutr. 2009;90:1236–1243.Dehghan P., Pourghassem Gargari B., Asghari Jafar-abadi M. Oligofructose-enriched inulin improves some infl ammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition. 2014;30:418– 423.Dehghan P., Pourghassem Gargari B., Asghari Jafar-abadi M. Oligofructose-enriched inulin improves some infl ammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial. Nutrition. 2014;30:418– 423.Sasaki M., Ogasavara N., Funaki Y. et al. Transglucosidase improves the gut microbiota profi le of type 2 diabetes mellitus patients: A randomized double-blind, placebo-controlled study. BMS Gastroenterol. 2013;13:81.Sasaki M., Ogasavara N., Funaki Y. et al. Transglucosidase improves the gut microbiota profi le of type 2 diabetes mellitus patients: A randomized double-blind, placebo-controlled study. BMS Gastroenterol. 2013;13:81.Anderson J.L., Edney R.J., Whelan K. Systematic review: faecal microbiota transplantation in the management of infl ammatory bowel disease. Aliment. Pharmacol. Ther. 2012;36:503–516.Anderson J.L., Edney R.J., Whelan K. Systematic review: faecal microbiota transplantation in the management of infl ammatory bowel disease. Aliment. Pharmacol. Ther. 2012;36:503–516.Smits L.P., Bouter K.E.C., de Vos W.M. et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946– 953.Smits L.P., Bouter K.E.C., de Vos W.M. et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946– 953.Kootte R.S., Vrieze A., Holleman F. et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab. 2012;14:112–120.Kootte R.S., Vrieze A., Holleman F. et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab. 2012;14:112–120.Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium diffi cile infection. Clin. Infect. Dis. 2011;53(10):994–1002.Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium diffi cile infection. Clin. Infect. Dis. 2011;53(10):994–1002.Grehan M.J., Borody T.J., Leis S.M. et al. Durable alteration of the colonic microbiota by the administration of donor fecal fl ora. J. Clin. Gastroenterol. 2010;44(8):551–561.Grehan M.J., Borody T.J., Leis S.M. et al. Durable alteration of the colonic microbiota by the administration of donor fecal fl ora. J. Clin. Gastroenterol. 2010;44(8):551–561.Vrieze A., Van Nood E., Holleman F. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.Vrieze A., Van Nood E., Holleman F. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.Karlsson F.H., Tremaroli V., Nookaev I. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.Karlsson F.H., Tremaroli V., Nookaev I. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.Qin J., Li Y., Cai Z. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.Qin J., Li Y., Cai Z. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.

The authors declare that there are no conflicts of interest present.